Patents by Inventor Ramulu Poddutoori
Ramulu Poddutoori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240016811Abstract: The present invention provides a combination of a substituted heterocyclyl derivative of formula (I) or a pharmaceutically acceptable salt thereof which is a CDK7 inhibitor along with an anti-microtubule agent or prodrug thereof, and a method of treating or preventing cancer in a subject, comprising administering to the subject a compound of formula (I) conjointly with the anti-microtubule agent.Type: ApplicationFiled: October 22, 2021Publication date: January 18, 2024Inventors: Akhil Kumar, Kishore Narayanan, Ramulu Poddutoori
-
Publication number: 20230250062Abstract: The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: ApplicationFiled: October 7, 2021Publication date: August 10, 2023Applicant: Aurigene Oncology LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Publication number: 20230212142Abstract: The present invention provides 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I), which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides the preparation of the compounds and pharmaceutical compositions that have at least one of the 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.Type: ApplicationFiled: March 31, 2020Publication date: July 6, 2023Applicant: Aurigene Discovery Technologies LimitedInventors: Ramulu Poddutoori, Susanta Samajdar, Subhendu Mukherjee
-
Publication number: 20220281871Abstract: The present invention provides substituted pyrazolo[1,3,5] triaziric and pyrazolo[1,5a] pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK15, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1,R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of disease or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaccutical formulations comprising at least one of the substituted pyrazolo [1.5-a] [1-3,5] triazine and pyrazolo[1,5-a] pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stercoisomer liner thereof.Type: ApplicationFiled: October 1, 2021Publication date: September 8, 2022Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Susanta Samajdar, Ramulu Poddutoori, Subhendu Mukherjee, Rajeev Goswami
-
Publication number: 20220194924Abstract: The present invention provides 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I), which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides the preparation of the compounds and pharmaceutical compositions that have at least one of the 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.Type: ApplicationFiled: March 31, 2020Publication date: June 23, 2022Applicant: Aurigene Discovery Technologies LimitedInventors: Ramulu Poddutoori, Susanta Samajdar, Subhendu Mukherjee
-
Publication number: 20220098156Abstract: The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: ApplicationFiled: October 7, 2021Publication date: March 31, 2022Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 11186576Abstract: The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1, R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.Type: GrantFiled: March 8, 2016Date of Patent: November 30, 2021Assignee: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 11174232Abstract: The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: GrantFiled: May 6, 2020Date of Patent: November 16, 2021Assignee: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 10894786Abstract: The present invention provides substituted pyrazole derivatives of formula (I) which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions with at least one of the substituted pyrazole derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.Type: GrantFiled: April 4, 2019Date of Patent: January 19, 2021Assignee: Aurigene Discovery Technologies LimitedInventors: Ramulu Poddutoori, Susanta Samajdar, Subhendu Mukherjee
-
Publication number: 20200308142Abstract: The present invention provides substituted pyrazole derivatives of formula (I) which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions with at least one of the substituted pyrazole derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.Type: ApplicationFiled: April 4, 2019Publication date: October 1, 2020Applicant: Aurigene Discovery Technologies LimitedInventors: Ramulu Poddutoori, Susanta Samajdar, Subhendu Mukherjee
-
Publication number: 20200262793Abstract: The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: ApplicationFiled: May 6, 2020Publication date: August 20, 2020Applicant: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 10689347Abstract: The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: GrantFiled: June 3, 2016Date of Patent: June 23, 2020Assignee: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 10544136Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.Type: GrantFiled: April 23, 2018Date of Patent: January 28, 2020Assignee: The Scripps Research InstituteInventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori
-
Publication number: 20190308951Abstract: The present invention provides substituted pyrazole derivatives of formula (I) which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions with at least one of the substituted pyrazole derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.Type: ApplicationFiled: April 4, 2019Publication date: October 10, 2019Applicant: Aurigene Discovery Technologies LimitedInventors: Ramulu Poddutoori, Susanta Samajdar, Subhendu Mukherjee
-
Publication number: 20190084947Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.Type: ApplicationFiled: April 23, 2018Publication date: March 21, 2019Inventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori
-
Publication number: 20180362471Abstract: The present invention provides substituted heterocyclyl derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: ApplicationFiled: June 3, 2016Publication date: December 20, 2018Applicant: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Publication number: 20180258092Abstract: The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1, R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.Type: ApplicationFiled: March 8, 2016Publication date: September 13, 2018Applicant: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 10011599Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.Type: GrantFiled: March 16, 2017Date of Patent: July 3, 2018Assignee: Novartis AGInventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
-
Publication number: 20180155293Abstract: The present invention provides substituted heterocyclyl derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: ApplicationFiled: June 3, 2016Publication date: June 7, 2018Applicant: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 9975863Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphingosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.Type: GrantFiled: September 22, 2017Date of Patent: May 22, 2018Assignee: The Scripps Research InstituteInventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori